Axel Grothey MDDirector, GI Cancer Research, West Cancer Center, Germantown, Tennessee
Axel Grothey, MD, is a medical oncologist and Director of Gastrointestinal Cancer Research at West Cancer Center and Research Institute, in Germantown, Tennessee.
Dr Grothey received his medical degree at Ruhr-Universität Bochum, Germany, and completed residencies at West German Tumor Center and the Institute of Pathology at the University of Essen and a residency and fellowship at the University of Bochum. He also completed a research fellowship at MD Anderson Cancer Center at the University of Texas. He joined Mayo Clinic as a consultant in 2005 and was appointed as Professor of Oncology in 2007. He left Mayo Clinic in summer of 2018 to join West Cancer Center.
Dr Grothey’s clinical interests focus on gastrointestinal cancers, in particular colorectal cancer, antiangiogenesis, signal transduction inhibitors, and clinical trial design and statistics. As a consultant and investigator, his research has been funded by the National Cancer Institute (NCI) and the National Institutes of Health, among other organizations. He currently co-chairs the NCI Gastrointestinal Cancer Steering Committee after having served as chair of the NCI Colon Cancer Task Force for 6 years. Until June 2018 he was vice chair of the Gastrointestinal Cancer Committee of the Alliance for Clinical Trials in Oncology, an NCI-funded cooperative group. He is also chaired the Academic and Community Cancer Research United (ACCRU) international research network based at Mayo Clinic until he joined West Cancer Center. He currently chairs the Research Council of the OneOncology network.
He currently holds professional positions in the Association of German Internists, German Cancer Association, Working Group of Experimental Cancer Research in Germany, American Association for Cancer Research, European Association for Cancer Research, American Society for Cell Biology, MD Anderson Associates, American Society of Clinical Oncology, European Society for Medical Oncology, German Association for Internal Oncology, and the Minnesota Medical Association.
Until 2018, Dr. Grothey was member of the NCCN Guidelines Committee for Colon, Rectal, and Anal Cancer. He is a member of the European Society of Medical Oncology (ESMO) guidelines committee for colorectal cancer.
Dr Grothey performs journal review and editorial activities for numerous medical journals and is editor for Clinical Colorectal Cancer, Emerging Cancer Therapeutics, PracticeUpdate, and Therapeutic Advances in Medical Oncology. He is a member of the editorial board of Journal of Clinical Oncology and Journal of the National Cancer Institute. In educational activities, he is a six-time recipient of Teacher of the Year recognition at Mayo Clinic. Dr Grothey has given numerous international, national, and regional presentations, as well as invited and visiting professor presentations. He has co-authored more than 500 articles, books, book chapters, editorials, abstracts, and letters.
Director of GI Cancer Research at West Cancer Center and Research Institute, Germantown, Tennessee
MD: Ruhr-Universitat Bochum, Germany
Fellowship (hematology/oncology): University of Bochum
Research fellowship (biochemistry and molecular biology): MD Anderson Cancer Center, The University of Texas
Colorectal cancer, anti-angiogenesis, signal transduction inhibitors, clinical trial design and statistics
The Mayo Clinic Foundation and West Clinic have received the following honoraria and grant support for activities conducted by Axel Grothey, MD:
Honoraria: Genentech/ Roche, Sanofi, Amgen, Eli-Lilly, Bayer, Bristol-Myers Squibb, Boston Biomedicals, Taiho, ARRAY.
Research grants: Genentech, Boston Biomedicals, ARRAY, Morphotek/ Eisai, Bayer, Sanofi, Daiichi, Merck.
Recent Contributions to PracticeUpdate:
- Pembrolizumab vs Chemotherapy in Advanced Esophageal Cancer
- Key Takeaways From ESMO: Gastroesophageal Cancer
- Key Takeaways From ESMO: Colorectal Cancer
- Surveillance After Curative Surgery for Colorectal Cancer
- Tumor Mutational Burden Associated With Outcomes in Patients With Advanced Solid Tumors Treated With Pembrolizumab
- mFOLFOXIRI With Cetuximab as Conversion Therapy in Patients With RAS/BRAF Wild-Type Unresectable Colorectal Liver Metastases
- Dabrafenib Plus Trametinib in Patients With BRAFV600E-Mutated Biliary Tract Cancer
- Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma
- Encorafenib and Binimetinib Plus Cetuximab for Untreated BRAF V600E-Mutant Metastatic Colorectal Cancer
- The Best of ESMO GI